Influence of Central Nervous Insulin Action on Insulin Sensitivity of Peripheral Organs in Lean Versus Overweight Humans

NCT ID: NCT02468999

Last Updated: 2016-01-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research in animals and first experiments in humans indicate that insulin action in the brain regulates peripheral insulin sensitivity. One major organ might be the liver. Previous studies in humans showed that the human brain is an insulin sensitive organ in lean but not in overweight/obese persons. Therefore, this study will include lean versus overweight/obese persons.

In this study, insulin action will be introduced by intranasal insulin administration in lean and overweight humans. As a control, placebo spray will be administered. To mimick the known spill over of small amounts of intranasal insulin into circulation, a small bolus of insulin will be administered over 15 minutes following placebo spray application.

Peripheral insulin sensitivity will be assessed by hyperinsulinemic-euglycemic glucose clamp and glucose uptake and endogenous glucose production will be assessed by tracer dilution technique. Autonomous nervous system activity will be addressed by heart rate variability. Involved brain areas will be addressed by fMRI before and after nasal insulin application.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insulin Resistance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

insulin nasal spray

160 Units of human insulin as nasal spray

Group Type ACTIVE_COMPARATOR

human insulin

Intervention Type DRUG

placebo nasal spray

Nasal spray containing placebo solution

Group Type PLACEBO_COMPARATOR

human insulin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

human insulin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male volunteers (lean or overweight/obese)
* HbA1c \<6.0%
* Age between 18 and 40 years
* healthy as assessed by physician
* Understanding the explanations about the study and instructions

Exclusion Criteria

* non-removable metal parts in or on the body
* Persons with reduced temperature sensation and / or increased sensitivity to warming of the body
* Cardiovascular disease can not be excluded, such as evident coronary heart disease, congestive heart failure NYHA greater than 2, history of coronary artery disease
* History of stroke
* Persons with a hearing disorder or increased sensitivity to loud noises
* People with claustrophobia
* Subjects in which less than 3 months have passed since surgery
* Simultaneous participation in other studies
* Acute disease or infection within the last 4 weeks
* Neurological and psychiatric disorders
* Subjects with hemoglobin Hb \<13g / dl
* Heparin-induced thrombocytopenia people with a (HIT) in prehistory
* Allergies to any of the used solutions/devices
Minimum Eligible Age

18 Years

Maximum Eligible Age

40 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital Tuebingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andreas Fritsche, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

University Hospital Tuebingen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Tuebingen, Department of Internal Medicine IV

Tübingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Heni M, Wagner R, Kullmann S, Gancheva S, Roden M, Peter A, Stefan N, Preissl H, Haring HU, Fritsche A. Hypothalamic and Striatal Insulin Action Suppresses Endogenous Glucose Production and May Stimulate Glucose Uptake During Hyperinsulinemia in Lean but Not in Overweight Men. Diabetes. 2017 Jul;66(7):1797-1806. doi: 10.2337/db16-1380. Epub 2017 Feb 7.

Reference Type DERIVED
PMID: 28174292 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

402/2014B01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Studies of Insulin and Glucagon Action in the Liver
NCT07300982 NOT_YET_RECRUITING PHASE1/PHASE2
Intranasal Glucagon and Energy Balance
NCT03650582 UNKNOWN PHASE2/PHASE3